HACKENSACK, N.J.—Royal Biologics has announced the launch of Cryo-Cord, reportedly the first viable, dimethyl sulfoxide (DMSO)-free umbilical cord graft. The company will showcase Cryo-Cord, along with its new portfolio of Autologous Live Cellular (ALC) technologies, at the NY20 Foundation for Podiatric Medicine meeting, held January 24-26 in New York, N.Y.
Royal Biologics will feature its full suite of surgical biologic offerings at exhibit booth #322, and on the podium for Innovation Theater presentations at 10:30 a.m. on Jan. 24 and 12 p.m. on Jan. 25. These presentations will feature several products within the Royal Biologics portfolio. At its booth, the company will showcase its comprehensive ALC portfolio, which is designed to personalize live regenerative healing for a wide variety of wound types across the orthopedics continuum.
Cryo-Cord has been obtained with consent from healthy mothers during cesarean section delivery. It is intended for use as a soft tissue barrier or wound dressing. The product is processed using aseptic techniques, and frozen with a proprietary cryoprotectant.
“Cryo-Cord offers a new enhancement to traditional wound care therapies, and we are excited to pave the way with the first DMSO-free cryoprotectant graft on the market,” said Salvatore Leo, chief executive officer of Royal Biologics.
Royal Biologics also plans to feature at NY20 their Maxx-Cell technology, which was launched as the world’s most advanced bone marrow aspiration device. Maxx-Cell offers a new technique, and it doesn’t require centrifugation to deliver a final end product. The Maxx-Cell system reportedly maximizes stem and progenitor cell yields by giving the surgeon the ability to efficiently harvest bone marrow from multiple levels within the medullary space, while restricting dilution of peripheral blood. As a result, Maxx-Cell delivers a high, pure enriched form of bone marrow aspirate.
This month, Royal Biologics also announced the launch of MAGNUS, which is a DMSO-free cellular bone allograft. Demonstrations will be available during the conference. MAGNUS differentiates itself from traditional cellular allograft technology by utilizing a DMSO-free cryoprotectant.
“We are excited to participate in NY20 and share how our Autologous Live Cellular based therapies give the surgeons an efficient and effective way to enhance surgical outcomes by providing alternatives to conventional therapies for bone and soft tissue related injuries,” added Leo. “We also believe that in a cost-conscious industry, we can provide novel viable cellular products that provide value at the point of care.”